Metformin and ageing: improving ageing outcomes beyond glycaemic control

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

In a world where the population is ageing, there is growing interest and demand for research evaluating strategies that address the ageing process. After 60 years of successful use of metformin in our pharmaceutical armamentarium, we are learning that, beyond improving glycaemic control, metformin may have additional mechanisms and pathways of action that need further study. Although, metformin’s effect on clinical ageing outcomes may still be considered speculative, the findings from studies into cellular and animal models and from observational and pilot human studies support the existence of beneficial effects on ageing. At present, progress for human research, using randomised clinical trials to evaluate metformin’s clinical impact, has just started. Here, we present a review on the ageing process and the mechanisms involved, and the role that metformin may have to counter these. We go on to discuss the upcoming large randomised clinical trials that may provide insight on the use of metformin for ageing outcomes beyond glycaemic control.

Original languageEnglish (US)
Pages (from-to)1630-1638
Number of pages9
JournalDiabetologia
Volume60
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Metformin
Randomized Controlled Trials
Research
Animal Models
Learning
Pharmaceutical Preparations
Population

Keywords

  • Ageing
  • Mechanisms of ageing
  • Metformin
  • Older adults
  • Review

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Metformin and ageing : improving ageing outcomes beyond glycaemic control. / Valencia, Willy Marcos; Palacio, Ana M; Tamariz, Leonardo; Florez, Hermes J.

In: Diabetologia, Vol. 60, No. 9, 01.09.2017, p. 1630-1638.

Research output: Contribution to journalReview article

@article{c9e5b763017646dfbcd88591342dc8ed,
title = "Metformin and ageing: improving ageing outcomes beyond glycaemic control",
abstract = "In a world where the population is ageing, there is growing interest and demand for research evaluating strategies that address the ageing process. After 60 years of successful use of metformin in our pharmaceutical armamentarium, we are learning that, beyond improving glycaemic control, metformin may have additional mechanisms and pathways of action that need further study. Although, metformin’s effect on clinical ageing outcomes may still be considered speculative, the findings from studies into cellular and animal models and from observational and pilot human studies support the existence of beneficial effects on ageing. At present, progress for human research, using randomised clinical trials to evaluate metformin’s clinical impact, has just started. Here, we present a review on the ageing process and the mechanisms involved, and the role that metformin may have to counter these. We go on to discuss the upcoming large randomised clinical trials that may provide insight on the use of metformin for ageing outcomes beyond glycaemic control.",
keywords = "Ageing, Mechanisms of ageing, Metformin, Older adults, Review",
author = "Valencia, {Willy Marcos} and Palacio, {Ana M} and Leonardo Tamariz and Florez, {Hermes J}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s00125-017-4349-5",
language = "English (US)",
volume = "60",
pages = "1630--1638",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Metformin and ageing

T2 - improving ageing outcomes beyond glycaemic control

AU - Valencia, Willy Marcos

AU - Palacio, Ana M

AU - Tamariz, Leonardo

AU - Florez, Hermes J

PY - 2017/9/1

Y1 - 2017/9/1

N2 - In a world where the population is ageing, there is growing interest and demand for research evaluating strategies that address the ageing process. After 60 years of successful use of metformin in our pharmaceutical armamentarium, we are learning that, beyond improving glycaemic control, metformin may have additional mechanisms and pathways of action that need further study. Although, metformin’s effect on clinical ageing outcomes may still be considered speculative, the findings from studies into cellular and animal models and from observational and pilot human studies support the existence of beneficial effects on ageing. At present, progress for human research, using randomised clinical trials to evaluate metformin’s clinical impact, has just started. Here, we present a review on the ageing process and the mechanisms involved, and the role that metformin may have to counter these. We go on to discuss the upcoming large randomised clinical trials that may provide insight on the use of metformin for ageing outcomes beyond glycaemic control.

AB - In a world where the population is ageing, there is growing interest and demand for research evaluating strategies that address the ageing process. After 60 years of successful use of metformin in our pharmaceutical armamentarium, we are learning that, beyond improving glycaemic control, metformin may have additional mechanisms and pathways of action that need further study. Although, metformin’s effect on clinical ageing outcomes may still be considered speculative, the findings from studies into cellular and animal models and from observational and pilot human studies support the existence of beneficial effects on ageing. At present, progress for human research, using randomised clinical trials to evaluate metformin’s clinical impact, has just started. Here, we present a review on the ageing process and the mechanisms involved, and the role that metformin may have to counter these. We go on to discuss the upcoming large randomised clinical trials that may provide insight on the use of metformin for ageing outcomes beyond glycaemic control.

KW - Ageing

KW - Mechanisms of ageing

KW - Metformin

KW - Older adults

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85026748623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026748623&partnerID=8YFLogxK

U2 - 10.1007/s00125-017-4349-5

DO - 10.1007/s00125-017-4349-5

M3 - Review article

C2 - 28770328

AN - SCOPUS:85026748623

VL - 60

SP - 1630

EP - 1638

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 9

ER -